Cofertility vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cofertility matches women who want to freeze eggs for their future with intended parents who need donor eggs, reducing the cost of freezing by sharing eggs with recipients.
About
Cofertility is a fertility technology company founded in 2021 that has created a unique egg sharing model connecting women who want to freeze their eggs with intended parents who need donor eggs. Through the platform's Split program, egg donors freeze half of their eggs for their own future use while the other half goes to recipients, with the recipient paying for the donor's entire egg freezing cycle. This arrangement makes egg freezing free for donors who would otherwise pay $10,000 or more out of pocket, while providing recipients with a younger, more diverse egg donor pool. Cofertility raised $30M and has built the largest technology-first egg donation platform, emphasizing donor safety, informed consent, and transparent compensation practices that differ from traditional egg donation agencies. The company screens donors and handles all clinical coordination with partner fertility clinics. Cofertility addresses both the financial barrier to egg freezing that prevents many women from accessing this preventive care and the limited supply of diverse egg donors that many intended parents face. The platform represents a novel market structure that creates value for donors, recipients, and the overall fertility ecosystem simultaneously.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.